Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer

International Journal of Cancer

Volumn 117, Issue 2, 2005, Pages 274-280

  Weikert, Steffen ^a   Krause, Hans ^a   Wolff, Ingmar ^a   Christoph, Frank ^a   Schrader, Mark ^a   Emrich, Thomas ^b   Miller, Kurt ^a   Müller, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Bladder cancer; Cytology; Diagnosis; Telomerase

Indexed keywords

BIOLOGICAL MARKER; RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME SUBUNIT; FOLLOW UP; GENE EXPRESSION REGULATION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY;

DNA-BINDING PROTEINS; FALSE POSITIVE REACTIONS; FEMALE UROGENITAL DISEASES; HUMANS; MALE UROGENITAL DISEASES; PROTEIN SUBUNITS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 25444526972     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21168     Document Type: Article

References (52)

1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
2. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986;135:920-2.
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD. Hawkins IR. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
4. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15:84-8.
5. Helpap B, Schmitz-Drager BJ, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters DJ, Droller MJ. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 2003;442:309-16.
6. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, Zwarthoff EC. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911-4.
7. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
8. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-28.
9. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985;29:810-6.
10. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993;37:163-9.
11. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18; discussion 18.
12. Simon MA, Lokeshwar VB, Soloway MS. Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 2003;47: 91-107.
13. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001;165:1067-77.
14. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002;167:75-9.
15. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998;4:1949-54.
16. Ito H, Kyo S, Kanaya T, Takakura M, Koshida K, Namiki M, Inoue M. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998;4:2807-10.
17. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-14.
18. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T, Yoshida O. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-30.
19. Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003;62:362-7.
20. Feng J, Funk WD, Wang SS, Weinnch SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
21. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
22. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
23. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002;21:643-9.
24. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5.
25. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-73.
26. Arai Y, Yajima T, Yagihashi A, Kobayashi D, Kameshima H, Sasaki M, Tanaka K, Kuwajima K, Miyao N, Tsukamoto T, Watanabe N. Limitations of urinary telomerase activity measurement in urothelial cancer. Clin Chim Acta 2000;296:35-44.
27. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001;10:677-85.
28. de Kok JB, Ruers TJ, van Muijen GN, van Bokhoven A, Willems HL, Swinkels DW. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem 2000; 46:313-8.
29. Schneider-Stock R, Emrich T, Peters B, Jaeger V, Roessner A. Analysis of human telomerase reverse transcriptase mRNA (hTERT) expression in myxoid liposarcomas using LightCycler real-time quantitative reverse transcriptase-polymerase chain reaction. Electrophoresis 2001;22:1098-101.
30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
31. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4:535-8.
32. Isurugi K, Suzuki Y, Tanji S, Fujioka T. Detection of the presence of catalytic subunit mRNA associated with telomerase gene in exfoliated urothelial cells from patients with bladder cancer. J Urol 2002;168(4 Pt 1):1574-7.
33. Neves M, Ciofu C, Larousserie F, Fleury J, Sibony M, Flahault A, Soubrier F, Gattegno B. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002;167:1276-81.
34. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996;56:645-50.
35. Maitra A, Rathi A, Gazdar AF, Sagalowsky A, Ashfaq R. Expression of the RNA component of human telemorase (hTR) in ThinPrep preparations from bladder washings. Cancer 2001;93:73-9.
36. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999; 162:1951-6.
37. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001;92:768-75.
38. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170(2 Pt 1):438-41.
39. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46: 170-6.
40. Murphy WM. Bladder cancer redefined. Cancer 1999;86:1890-2.
41. Curry JL, Wojcik EM. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results. Cancer 2002;96:140-5.
42. Whisnant RE, Bastacky SI, Ohori NP. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification. Diagn Cytopathol 2003;28:186-90.
43. Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Hum Pathol 2000;31:745-50.
44. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002;441:109-16.
45. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002; 441:105-8.
46. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315-20.
47. Hotakainen K, Lintula S, Stenman J, Rintala E, Lindell O, Stenman UH. Detection of messenger RNA for the beta-subunit of chorionic gonadotropin in urinary cells from patients with transitional cell carcinoma of the bladder by reverse transcription-polymerase chain reaction. Int J Cancer 1999;84:304-8.
48. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
49. Malik SN, Murphy WM. Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice. Urology 1999;54:62-6.
50. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MG Jr, Silberman SR, Butman BT. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158(3 Pt 1):801-5.
51. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Stemberg CN, Boccon-Gibod L, Ravery V, Le Guludec D, Meulemans A, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45: 472-7.
52. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.